Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release

COO Alexander Karle appointed CEO of Evaluate Ltd

Evaluate Founder, Jonathan de Pass to become Chairman

Download PDF

LONDON, BOSTON, TOKYO (Sept 1, 2014) - Life science market intelligence company, Evaluate Ltd, today announced the appointment of Alex Karle to the role of Chief Executive Officer. Dr Jonathan de Pass, founder and Chief Executive Officer for the last 18 years will become Chairman of the Board. These appointments are effective immediately.

Since founding Evaluate in March 1996, Dr de Pass has overseen the development of the company into a world leader in market intelligence and analysis for the life science sector. Over the years Evaluate has created many new industry standards for forecasting global drug sales and other industry performance metrics resulting in uninterrupted sales growth compounding at 20% per annum over the last 10 years.

As Chief Operating Officer, Mr Karle has been responsible for sales, marketing and business development for Evaluate, and the creation of new products and software capabilities. Since joining Evaluate in 2012 as Chief Operating Officer, he has played a critical role in the launch of EvaluateMedTech, setting a new standard in integrated analysis and consensus forecasts for the medical device and diagnostic industry. 

Prior to his role at Evaluate, Mr Karle served as Vice President, Strategy & Development of IP & Science at Thomson Reuters. Mr Karle began his career as a Senior Associate at Booz Allen & Hamilton. He holds an MBA from Yale University and a BA in Business, Economics and Law from the European Business Programme in Germany.

“It’s been an absolute privilege and a joy working with so many talented colleagues and clients over the years” said Dr de Pass. “Together we have built an exceptional business that is trusted by a blue chip client base of major companies and institutions from around the world”.

He added, “It’s now time to hand the reins over to Alex. Under his leadership and supported by a first class team, I’m confident that Evaluate is in excellent hands and will continue to develop its services to provide ever more benefits for our clients. I congratulate Alex on his appointment.”

“With his drive and vision, Jonathan has created a world leading organisation and he has set a very high standard. I am very much looking forward to taking on the CEO position,” said Mr Karle. “It is important to me that Jonathan will remain an integral part of the team as Chairman. His knowledge and insight will be invaluable as we continue to expand Evaluate’s products and services in close partnership with our clients across the Pharmaceutical and Medical Devices industry.”


About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems. Our award-winning editorial team, EP Vantage, leverages our market intelligence and analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial.

Back to Press Releases